EFSA speaks on disputed lutein claims: Only “normal vision” eligible
date:Jun 16, 2012
s in 2004 that is infuriating the lutein sector, none more than the biggest players, DSM and Kemin.

level of unclarity that's unprecedented

The companies sent us a statement expressing their frustration at the NDAs trajectory on the matter, while remaining upbeat a claim could be won.

The opinion of EFSA presents us with a level of unclarity that's unprecedented,said DSM VP of nutrition and health, Bas van Buijtenen.

EFSA has apparently come to the conclusion that the evidence on lutein and
3/8 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/24 00:17